Prognostic Impact of Age and Hemoglobin in Acute ST-Segment Elevation Myocardial Infarction Treated With Reperfusion

Jesús Velásquez-Rodríguez1, Felipe Diez-Delhoyo1, María Jesús Valero-Masa1

  • 1Department of Cardiology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERCV, Madrid, Spain.

Insights

In ST-segment elevation myocardial infarction (STEMI) patients, higher hemoglobin levels independently predict better survival. This association holds true for older individuals, including men with normal hemoglobin levels, highlighting its prognostic significance.

Area of Science:

  • Cardiology
  • Internal Medicine
  • Clinical Research

Background:

  • Advanced age and low hemoglobin levels are linked to poorer outcomes in ST-segment elevation myocardial infarction (STEMI).
  • Understanding prognostic factors in STEMI is crucial for improving patient management and survival rates.

Purpose of the Study:

  • To investigate the independent predictive value of hemoglobin levels on mortality in patients with STEMI.
  • To assess the association between hemoglobin levels, age, and prognosis in STEMI patients receiving reperfusion therapy.

Main Methods:

  • A cohort of 1,111 STEMI patients treated with reperfusion therapy (primary angioplasty or fibrinolysis) was analyzed.
  • Multivariate analysis was employed to identify predictors of in-hospital and long-term mortality, including age and hemoglobin levels.
  • Subgroup analyses were performed to examine the association of hemoglobin with mortality across different age groups and sexes.

Main Results:

  • Age was identified as an independent predictor of both in-hospital and long-term mortality in STEMI patients.
  • Lower hemoglobin levels at admission were significantly associated with increased mortality.
  • The prognostic value of hemoglobin was observed in older patients (≥65 years), including men with normal hemoglobin levels.

Conclusions:

  • Hemoglobin level is an independent predictor of in-hospital and long-term mortality in STEMI patients.
  • The association between hemoglobin and mortality is particularly significant in patients aged 65 years and older.
  • These findings suggest that hemoglobin levels should be considered in the risk stratification of STEMI patients.

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.0K
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.3K
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
288